Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd. has achieved significant milestones in its commercialization efforts, including recording its first revenue from CE-Marked Nu.Q NETs automated assay sales and expanding evaluations to over 20 hospitals across 10 countries. The company has established key partnerships for human diagnostics, notably with Werfen and Hologic, bolstering its market presence and potential for broader oncology applications. Additionally, advancements in technology and a strong foothold in both human and veterinary diagnostics highlight VolitionRX's strategic position for future growth and increased healthcare utilization efficiency.

Bears say

VolitionRX Ltd faces significant dilution risk that negatively impacts its financial outlook, compelling a reduction in its valuation from $5.00 to $3.00. This dilution risk suggests potential challenges in raising sufficient capital without adversely affecting shareholder value. Consequently, the company's ability to sustain its growth trajectory and fund ongoing development of its diagnostic platform may be hindered, raising concerns among investors.

Volitionrx Limited (VNRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.